The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...
The U.S. Food and Drug Administration has approved Inlexzo (gemcitabine intravesical system) for the treatment of patients with certain types of bladder cancer. Specifically, Inlexzo is indicated for ...
Bladder cancer patients who have an early but aggressive form of the disease that’s unresponsive to the standard of care now have a new treatment option, an implanted Johnson & Johnson drug/device ...
Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder ...
Please provide your email address to receive an email when new articles are posted on . Most patients with non-muscle-invasive bladder cancer who received TAR-200 with gemcitabine achieved complete ...
Johnson & Johnson received Food and Drug Administration approval for Inlexzo, a treatment for people with bladder cancer. The treatment is designed for patients seeking to avoid bladder removal. It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results